A new clinical trial, the ReCIPE-M1 study, is exploring an innovative way to treat advanced melanoma (a type of skin cancer) by combining therapeutic plasma exchange (TPE) with existing cancer immunotherapy. The goal is to improve the effectiveness of immunotherapy, which currently works for only about one-third of patients and eventually loses effectiveness for most.
Key Points:
- Melanoma cells release molecules (sPD-L1 and evPD-L1) into the blood that weaken the immune system and make immunotherapy less effective.
- TPE is a procedure that removes these harmful molecules from the blood, potentially restoring the immune system’s ability to fight the cancer.
- In this trial, patients receive a combination of TPE, immunotherapy, and targeted radiation to test if TPE can make treatment safer and more effective.
- The study’s primary goal is to assess the safety of TPE, with secondary goals to track cancer response and molecule levels in the blood.
If successful, this approach could expand to treat other cancers and pave the way for more effective immune-based therapies.
